Overview
Ibogaine is a naturally occurring indole alkaloid associated with the West African shrub Tabernanthe iboga, and modern medical interest has focused on its reported ability to reduce withdrawal and craving in some people with substance use disorders.[1] For background on the plant source, see Tabernanthe Iboga: The Plant Behind Ibogaine.[1]
Ibogaine is not established as a standard medical treatment for opioid use disorder, stimulant use disorder, PTSD, traumatic brain injury, depression, or anxiety, and the clinical literature remains limited by small samples, open-label designs, heterogeneous protocols, and incomplete long-term follow-up.[1] In the United States, ibogaine is listed as a Schedule I controlled substance, which restricts clinical use outside authorized research settings.[2]
The strongest recurring clinical signal is short-term interruption of opioid withdrawal, but this finding has not yet been confirmed by large, completed Phase III trials comparing ibogaine with evidence-based treatments such as buprenorphine, methadone, or extended-release naltrexone.[1] For a condition-specific discussion, see Ibogaine for Opioid Addiction and Ibogaine Treatment for Addiction.[3]
Mechanisms Relevant to Clinical Trials
Ibogaine has a complex pharmacology and does not behave like a conventional single-target addiction medication.[1] It is metabolized in part to noribogaine, a longer-lasting metabolite that has been proposed to contribute to post-acute effects on withdrawal, craving, and mood.[4]
- Opioid-related activity: Human pharmacokinetic and detoxification research has linked ibogaine and noribogaine exposure with reductions in opioid withdrawal signs in open-label settings.[4]
- Glutamate and NMDA systems: Reviews describe NMDA receptor interactions as one possible pathway through which ibogaine may affect tolerance, withdrawal, and addiction-related learning.[1]
- Serotonin and monoamine systems: Noribogaine has been discussed as a compound with monoamine reuptake effects, which may be relevant to mood and craving outcomes reported in some studies.[1][4]
- Neuroplasticity hypotheses: Ibogaine-inspired compounds such as tabernanthalog have been developed to test whether iboga-like neuroplastic effects can be separated from hallucinogenic and cardiotoxic liabilities.[5]
- Cardiac ion-channel effects: Ibogaine and noribogaine can affect cardiac electrophysiology, including hERG potassium channel activity, which is a major reason trials use ECG screening and monitoring.[6]
Registered and Ongoing Clinical Trials
Several modern ibogaine studies are registered or structured as clinical investigations, but the field still lacks completed, large, multicenter Phase III trials with regulatory-grade efficacy and safety data.[1][7][8]
- NCT04003948, IBO-METAD-001: This Phase II study in Spain evaluates preliminary efficacy and safety of ibogaine hydrochloride for people tapering from methadone, with outcomes including methadone dose reduction, adverse events, and ECG measures such as QT and ST intervals.[7] The protocol uses low or ascending oral doses rather than a single high-dose “flood” approach, reflecting concern about cardiac risk.[7]
- NCT05029401: This registered Phase 1/2a study examines oral ibogaine in opioid withdrawal and includes dose-escalation elements intended to characterize safety and tolerability before broader efficacy testing.[8]
- UC Irvine neuroimaging study: Researchers at the University of California, Irvine reported a grant-supported observational study using pre- and post-treatment neuroimaging and clinical measures in people receiving ibogaine treatment for opioid use disorder outside the United States.[9]
- Texas-funded research initiative: In 2026, Texas officials and researchers described a state-backed ibogaine research effort intended to support clinical development for addiction and traumatic brain injury, although such programs still require regulatory authorization, trial execution, and peer-reviewed results before clinical claims can be established.[10] For the policy context, see Ibogaine Treatment in Texas and Rick Perry Ibogaine Advocacy.[10]
Clinical Evidence for Substance Use Disorders
A 2022 systematic review identified a small and heterogeneous human literature on ibogaine for substance use disorders, with evidence suggesting possible reductions in withdrawal and craving but with major limitations in study design and follow-up.[1] The review’s overall conclusion was that ibogaine remains promising but insufficiently proven, especially because many studies were observational, uncontrolled, or conducted in treatment settings that combined ibogaine with medical and psychosocial support.[1]
Mash and colleagues published early human pharmacokinetic and clinical observations in heroin withdrawal, reporting rapid metabolism to noribogaine and reductions in withdrawal measures after ibogaine administration in an open-label context.[4] A later retrospective analysis of data from the Healing Visions Institute in St. Kitts described outcomes among people treated for opioid and cocaine dependence, but the design lacked randomization and could not isolate ibogaine effects from the surrounding clinical program.[11]
Brown and Alper conducted a prospective observational follow-up study of people receiving ibogaine for opioid use disorder at a clinic in Mexico and reported reductions in opioid withdrawal and some self-reported reductions in opioid use after treatment.[3] Noller, Frampton, and Yazar-Klosinski reported a 12-month observational follow-up in New Zealand, where some participants reported decreased opioid use or abstinence after legally prescribed ibogaine treatment, but the sample was small and uncontrolled.[12]
In Brazil, Schenberg and colleagues published a retrospective study of ibogaine-assisted treatment combined with psychotherapy in people with alcohol, cannabis, cocaine, crack cocaine, and polysubstance dependence, reporting periods of abstinence in some participants.[13] Because these studies do not establish superiority over standard medications, ibogaine should not be presented as a proven replacement for methadone, buprenorphine, or naltrexone.[1]
PTSD, TBI, and Neuropsychiatric Research
Interest in ibogaine expanded beyond addiction after an open-label study of magnesium–ibogaine therapy in U.S. veterans with traumatic brain injuries. Special Operations Forces veterans with histories of traumatic brain injury.[14] The study reported improvements at one month in self-reported disability, PTSD symptoms, depression, anxiety, and some neuropsychological measures, while also reporting no serious adverse events in the monitored cohort.[14]
The veteran study was uncontrolled and open-label, meaning expectancy effects, selection bias, concurrent support, and regression to the mean cannot be excluded.[14] Its findings are therefore best interpreted as hypothesis-generating rather than proof that ibogaine is effective for PTSD or traumatic brain injury.[14]
For deeper reviews of these indications, see Ibogaine for PTSD, Ibogaine for TBI, and Ibogaine Treatment for Depression & Anxiety.[14]
Safety Risks in Trials and Treatment Settings
Safety is the central barrier to ibogaine’s clinical development, and cardiac risk is the most prominent concern.[6] Ibogaine can prolong cardiac repolarization and is associated with QT interval prolongation, which can increase the risk of torsades de pointes and sudden cardiac death in susceptible people.[6]
Reported risk factors include pre-existing cardiac disease, prolonged baseline QTc, electrolyte abnormalities, bradycardia, liver impairment, high dose exposure, methadone or other QT-prolonging drugs, stimulant use, and uncertain product purity in nonmedical settings.[6][15] Fatality reviews have described deaths temporally associated with ibogaine ingestion, often involving cardiac disease, comorbid illness, or co-use of other substances.[15][16]
Common acute adverse effects reported across the literature include nausea, vomiting, ataxia, tremor, dizziness, insomnia, perceptual changes, anxiety, and prolonged fatigue.[1] Serious concerns include arrhythmia, seizure, delirium, aspiration during vomiting, dehydration, falls, and psychiatric destabilization in vulnerable individuals.[6][15] For a dedicated safety review, see Ibogaine Side Effects.[15]
Trial Protocols, Screening, and Monitoring
Modern clinical protocols emphasize medical screening, dose caution, and cardiac monitoring because ibogaine’s potential benefits must be weighed against acute physiological risk.[6][7] Registered studies such as NCT04003948 explicitly include ECG monitoring and adverse-event assessment soon after dosing.[7]
A medically conservative research or treatment protocol generally includes medical history review, medication reconciliation, ECG with QTc assessment, electrolyte testing, liver and kidney function testing, psychiatric screening, and assessment of substance withdrawal risk.[6][7] Trials and higher-quality clinical programs may exclude participants with cardiac disease, prolonged QTc, unstable psychiatric illness, or interacting medications.[7][15]
Unregulated treatment settings vary widely in screening, product quality, staffing, emergency preparedness, integration, and aftercare, which complicates interpretation of observational outcomes.[1][15] For practical clinic-selection considerations, see Ibogaine Treatment Centers, Ibogaine Clinics, and How to Get Ibogaine Treatment Safely.[15]
Legal and Regulatory Context
Ibogaine’s legal status strongly affects where clinical trials and treatment programs operate.[2] In the United States, ibogaine is listed in Schedule I under federal controlled-substance regulations, so possession, administration, and research require special legal authorization.[2]
Because U.S. access is restricted, many observational studies and treatment reports come from jurisdictions where ibogaine has been available through private clinics, prescription pathways, or less restrictive regulatory environments.[3][12] Mexico, New Zealand, Brazil, Spain, and Caribbean jurisdictions have all contributed to the modern clinical literature or trial landscape, but legal permissibility does not by itself establish medical safety or efficacy.[3][7][12][13]
For country-by-country and U.S. state discussions, see Ibogaine Legality by Country, Ibogaine Treatment in the United States, Ibogaine Treatment in Mexico, and Ibogaine Drug Classification.[2]
Future Research Directions
The most important next step for ibogaine research is the completion of well-controlled trials that can separate drug effects from expectancy, withdrawal management, psychotherapy, residential support, and aftercare.[1] Priority designs include ibogaine versus standard opioid detoxification, ibogaine-assisted transition to extended-release naltrexone, ibogaine plus structured psychotherapy versus psychotherapy alone, and randomized trials in PTSD or traumatic brain injury populations.[7][14]
Mechanistic studies are also important because neuroimaging and biomarker work may clarify whether clinical changes correlate with alterations in brain connectivity, stress circuitry, or neuroplasticity markers.[9] Pharmacogenomic research may also be relevant because metabolism to noribogaine and individual susceptibility to cardiac effects could affect both efficacy and safety.[4][6]
Another major direction is the development of ibogaine analogs that aim to preserve anti-addictive or neuroplastic effects while reducing hallucinogenic intensity and cardiac toxicity.[5] Tabernanthalog is one example of an ibogaine-inspired compound reported in preclinical work to promote structural neural plasticity and reduce drug-seeking behavior in animal models, but it is not ibogaine and remains investigational.[5]